What is drug repurposing and why is it relevant?

In this Online SPARK Europe Webinar "What is drug repurposing and why is it relevant?", Hans Platteeuw will talk about the pros and cons of developing a new chemical entity as a drug, as well as the opportunities and challenges of repurposing and possible solutions.


MS Teams

Hans is a chemist by training. He has a long-standing experience in product development in both the innovator, generics and value-added medicines industry. He is a founder and Chief Scientific Officer of Galenicap, a company fully dedicated to the development of New Therapeutic Entities.

The Webinar will be hosted by SPARK-BIH.

Online via MS Teams | Please register here!

Registration to the webinar is required in advance. Please register no later than 5 March 2024. Please note that you will receive the Zoom link and access code the evening before the lecture and that access to last minute registrations, cannot be guaranteed.

SPARK Europe is the joint network of SPARK sites all over Europe including Israel: SPARK-BIH, SPARK Finland, SPARK FLI, SPARK Norway, SPARK Poland, SPARK Tel Aviv, SPARK Denmark and SPARK Zürich. European SPARK programs are members of SPARK Global network. The purpose of SPARK programs is to provide the education and mentorship necessary to advance research discoveries from the bench to the bedside, hence to increase the maturity of academic and clinical discoveries towards practical solutions that address unmet needs in the life science and health tech space. The program follows the same principles that have been the cornerstones of SPARK at Stanford since it was established by Professor Daria Mochly-Rosen and Kevin Grimes in 2006 for advancing new biomedical research discoveries into promising new treatments for patients.


SPARK-BIH is a member of the SPARK Global network